MA-ROCKET-SOFTWARE
Rocket Software , a global technology leader that develops enterprise software used by the world’s largest public and private sector companies, today named Milan Shetti the company’s next CEO, effective November 5. Milan will also retain his President title. Current CEO and co-founder Andy Youniss will become Executive Chairman, providing strategic insights and guidance to Rocket® in important areas where he has experience and expertise. Andy will also remain on Rocket’s Board of Directors.
“From Rocket’s creation almost 32 years ago, we set out to build a long-lasting software company that would make a difference in the world,” Youniss said. “I am incredibly proud of the company we have built, our 2,500 Rocketeers, the culture we embody, and the core values we live every day. This leadership transition is deeply important to me, and we have been intentional and thoughtful in every step of the process.”
Shetti joined Rocket in 2020 as Business Unit President and was named Rocket President earlier this year, overseeing all products in the company’s portfolio. Most recently, he held senior executive positions at Hewlett Packard Enterprise (HPE), including serving as Senior Vice President and General Manager of the multi-billion dollar storage business unit and previously as Chief Technology Officer of the Datacenter Infrastructure and Storage divisions.
“Milan is the right leader for this moment in Rocket’s history and for its future,” Youniss continued. “I have the utmost confidence that under his leadership, Rocket will continue to put our customers and partners first, deliver innovation and quality that matters, and enable even more legendary outcomes."
“I was captivated by how Rocket’s culture and technology strengthen each other,” said Shetti. “The connection Andy created between Rocket’s core values and the way we serve our customers and partners is what excites me most about leading Rocket in this next era, as we continue to accelerate the modernization of mission-critical systems and solve our customers’ and partners’ most pressing, highly technical challenges.”
“Andy has done a remarkable job building Rocket Software into a global technology leader, thoughtfully guiding the company’s growth and success. We are delighted to be able to continue working with him at the board level,” said David Humphrey, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
“Milan is an established technology leader with deep background in infrastructure management solutions. We are confident his skills and experience will enable Rocket to continue to advance its mission-critical portfolio of enterprise software solutions while furthering the commitment to its customers, employees and business partners,” added Max de Groen, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
Shetti began his career at Sun Microsystems as a software developer and advanced through a technical career path to technical director for the company’s data management group. After Sun Microsystems, Shetti led business development for IBRIX, Inc. before assuming the chief executive position. He holds a PhD in computer science from the University of Minnesota and a Master of Science in computer engineering from Syracuse University.
About Rocket Software
Rocket Software empowers organizations to create legendary impact in the world through innovation in legacy technologies. With deep expertise in IBM Z®, IBM Power®, and database and connectivity solutions, Rocket provides solutions that power tens of thousands of global businesses, solving real problems and making real-world impact. Rocket is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia, and Australia. Rocket is a portfolio company of Bain Capital Private Equity.
Legacy Powers Legendary™
© 2021 Rocket Software, Inc. or its affiliates. All Rights Reserved.
Rocket® is a trademark of Rocket Software, Inc. and its subsidiaries, registered in the United States and other jurisdictions worldwide. All other trademarks cited herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom